New drug aims to lower dangerous oxalate levels in rare kidney disease
Disease control
Not yet recruiting
This study tests a new medicine, YOLT-203, in children and adults with primary hyperoxaluria type 1, a rare genetic condition that causes harmful oxalate buildup. The trial will compare YOLT-203 to a placebo over 6 months to see if it safely reduces oxalate levels in urine and bl…
Phase: PHASE2 • Sponsor: YolTech Therapeutics Co., Ltd • Aim: Disease control
Last updated May 15, 2026 11:53 UTC